AbbVie Wins EU Approval for RINVOQ
AbbVie's RINVOQ approved for severe alopecia areata
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AbbVie Extends Reach Across Dermatology Markets With Dual Regulatory Wins
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.’s (NYSE: ABBV ) SKYRIZI (risankizumab-rzaa) for children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. A new 55 mg pre-filled syringe